Affect Therapeutics Secures $16 Million in Series A Funding to Revolutionize Addiction Recovery

Key Takeaways:

1. Affect Therapeutics raised $16 million in a recent Series A funding round.
2. The health tech startup uses mobile technology to aid stimulant addiction recovery.
3. Leading the round was Artis Ventures (AV), with participation from AlleyCorp, City Light Capital, LifeArc Ventures, Samsung NEXT, and What If Ventures.
4. The successful round brings Affect Therapeutics’ total funding to $23 million.

Affect Therapeutics, an innovative health tech startup, announced today it has raised $16 million in a Series A funding round. The round was led by Artis Ventures (AV), with participation from AlleyCorp, City Light Capital, LifeArc Ventures, Samsung NEXT, and What If Ventures.

The funding comes as a testament to the company’s commitment to revolutionizing the fitness, health care, and wellness industries. Their unique model leverages the power of mobile technology to redefine and innovate the way stimulant addiction recovery is approached and managed.

Affect Therapeutics, as the company’s name implies, is centered around affecting positive changes in the lives of those struggling with stimulant addiction. By integrating mobile technology into recovery processes, they aim to make significant strides in managing and overcoming addiction.

This successful Series A round brings the total amount of funding raised by Affect Therapeutics to $23 million across four rounds. The capital will be used to enhance and extend their mobile technology platform, further supporting individuals in their journey towards recovery.

Artis Ventures (AV), the lead investor, is a well-respected figure in the investment landscape. Their backing of Affect Therapeutics signals a strong belief in the innovative approach of this groundbreaking startup.

The other participating investors, including AlleyCorp, City Light Capital, LifeArc Ventures, Samsung NEXT, and What If Ventures, all hold impressive portfolios in the tech industry. Their collective support illustrates a shared vision of transforming the way addiction recovery is managed in the healthcare industry.

For more information about Affect Therapeutics and their mission, visit their Crunchbase profile.

The world of healthcare is eagerly watching as Affect Therapeutics prepares to put these new funds to use, promising to bring a wave of positive changes in addiction recovery.

Ready to amplify your reach and engage with the most dynamic community in the venture world? Consider sponsoring an article with us. Learn more about our promotional opportunities and sponsored articles here.

Your story could be the next big hit on US Venture News!